Noriega IMF, Arias SEA, García LSMC

Language: Spanish
References: 23
Page: 196-202
PDF size: 65.03 Kb.

ABSTRACT

There are different hypertensive disorders that occur during pregnancy, which are among the most common complications and represent an important cause of maternal and perinatal morbidity and mortality. It is of great importance the opportune diagnosis and optimal treatment of each specific complication in order to improve the fetal outcome and postpartum. It is also imperative to achieve the knowledge of the specific treatment, since it is essential to be aware of the potential adverse effects on the fetus of the different drugs used in non pregnant hypertensive women.

REFERENCES

1. Baha MS. Treatment of hypertension in pregnant women. NEJM 1996; 335: 257-265

2. Zareian Z. Hypertensive disorders of pregnancy. Int J Gynaecol Obstet 2004; 87: 194-198.

3. Makhseed V, Musini VM, Ahemed MA. Association of fetal gender with pregnancy-induced hypertension and pre-eclampsia. Int J Gynaecol Obstet 1998; 63: 55-56.

4. Cunningham FG, Lindheimer MD. Hypertension in pregnancy. NEJM 1992; 326: 927.

5. Laskowska M, Laskowska K, Oleszczuk J. Angiotensin-converting enzyme activity in pre-eclampsia. Int J Gynaecol Obstet 2002; 77: 33-34.

6. Vigil-De Gracia P, Lasso M, Montufar-Rueda C. Perinatal outcome in women with severe chronic hypertension during the second half of pregnancy. Int J Gynaecol Obstet 2004; 85: 139-144.

7. Vanek M, Sheiner E, Levy A, Mazor M. Chronic hypertension and the risk of adverse pregnancy outcome after superimposed preeclampsia. Int J Gynaecol Obstet 2004; 86: 7-11.

8. Brown CE, Grant NF, Cox K et al. Low dose aspirin. Relationship of angiotensin II pressor responses, circulating eicosanoids, and pregnancy outcome. Am J Obstet Gynecol 1990; 163: 1853.

9. Shotan A, Widerhorn J et al. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 1994; 96: 451.

10. Siba BM. Magnesium sulfate prophylaxis in preeclampsia: lessons learned from recent trials. Am J Obstet Gynecol 2004; 190: 1520.

11. Helewa ME, Burrows RF et al. Report of the canadian hypertension society consensus conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. CMAJ 1997; 157: 715.

12. American College of Obstetricians and Gynecologists. Diagnosis and management of preeclampsia and eclampsia. ACOG practice bulletin # 33. Washington DC 2002.

13. Sibai BM. Pitfalls in diagnosis and management of preeclampsia. Am J Obstes Gynecol 1988; 159: 1.

14. Sibai BM, Mercer B et al. Sever preeclampsia in the second trimester: recurrent risk and long term prognosis. Am J Obstet Gynecol 1991; 165: 1408.

15. Hall DR, Odendaal HJ, Smith M. Is the prophylactic administration of magnesium sulfate in women with preeclampsia indicated prior labor? BJOG 2000; 107: 903.

16. Dekker GA, Sibai BM. Low dose aspirin in the prevention of preeclampsia and fetal growth retardation: rationale, mechanisms and clinical trials. Am J Obstet Gynecol 1993; 168: 214.

17. Beaufils M, Uzan S et al. prevention of preeclampsia by early antiplatelet therapy. Lancet 1985; 1: 840.

18. Schubiger G, Flury G, Nussberger J. Enalapril poor pregnancy induced hypertension: acute renal failure in a neonate. Ann Intern Med 1988; 108: 215.

19. National High Blood Pressure Educational Program Working Group report on high blood pressure on pregnancy. Am J Obstet Gynecol 1990; 163: 1691-712.

20. Sibai BM, Akl S, Fairlie F, Moretti M. A protocol for managing severe preeclampsia in the second trimester. Am J Obstet Gynecol 1990; 163: 733-8.

21. Collins R, Yusuf S, Peto R. Overview of randomized trials of diuretics in pregnancy. BMJ 1985; 290: 17-23.

22. Rosa FW, Bosco LA, Graham CF, Milstien JB, Dreis M, Creamer J. Neonatal anuria with maternal angiotensin-converting enzyme inhibition. Obstet Gynecol 1989; 74: 371-4.

23. Lopez-Llera M. Main clinical types and subtypes of eclampsia. Am J Obstet Gynecol 1992; 166: 4-9.